Evaluating efficacy and safety of Unani drug in Sayal ?n al-Ra?im (Leucorrhoea)
- Conditions
- Health Condition 1: N949- Unspecified condition associated with female genital organs and menstrual cycle
- Registration Number
- CTRI/2023/10/058205
- Lead Sponsor
- ational Research Institute Of Unani Medicine For Skin Disorders
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
i) Female patients in the age group of 13-45 years
ii) Patients of Sayal ?n al-Ra?im (Leucorrhoea) having the following symptoms:
a) Excessive white or creamy vaginal discharge evident from persistent vulvar moistness or staining of the undergarments (brownish-yellow stain on drying) or need to wear a vulvar pad, with or without any of the following associated symptoms:
b) Waja‘ al-Kh ??ira (Low Backache)
c) ?u’f-i-‘Am (General Weakness)
d) Non-infective Leucorrhoea
i) Age below 13 years and above 45 years
ii) Patients with Pelvic Inflammatory Disease (PID), Infective leucorrhea
iii) Positive History of Venereal Disease/ Sexually Transmitted Disease (Syphilis, Gonorrhoea)
iv) Patients using oral contraceptive pills (OCPs), intrauterine contraceptive device (IUCD), hormone therapy, and any long-term medications
v) Significant Pulmonary/Cardiovascular/Hepato-Renal Dysfunction
vi) Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies
vii) Post-delivery or post-abortion period of <6 weeks
viii) Pregnant and lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in Discharge per vaginum from baseline after treatment of 6 weeks <br/ ><br>Timepoint: 42 Days
- Secondary Outcome Measures
Name Time Method i) Relief in Low Backache <br/ ><br>ii) Improvement in symptoms of generalized weakness <br/ ><br>iii) Systemic Safety assessmentTimepoint: 42 Days